دورية أكاديمية

Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.

التفاصيل البيبلوغرافية
العنوان: Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
المؤلفون: Borah P; Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-26, Assam, India., Deb PK; Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, PO Box 1, Amman 19392, Jordan., Venugopala KN; Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia., Al-Shar'i NA; Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan., Singh V; Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch, 7701, South Africa., Deka S; Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-26, Assam, India., Srivastava A; Neuroscience and Pain Research Lab, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, 221 005, India., Tiwari V; Neuroscience and Pain Research Lab, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, 221 005, India., Mailavaram RP; Department of Pharmaceutical Chemistry, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram - 534 202, West Godavari Dist., Andhra Pradesh, India.
المصدر: Current topics in medicinal chemistry [Curr Top Med Chem] 2021; Vol. 21 (6), pp. 547-570.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 101119673 Publication Model: Print Cited Medium: Internet ISSN: 1873-4294 (Electronic) Linking ISSN: 15680266 NLM ISO Abbreviation: Curr Top Med Chem Subsets: MEDLINE
أسماء مطبوعة: Publication: Saif Zone, Sharjah, U.A.E. : Bentham Science Publishers
Original Publication: Hilversum, The Netherlands : Bentham Science Publishers, c2001-
مواضيع طبية MeSH: Antitubercular Agents/*pharmacology , Drug Resistance, Multiple, Bacterial/*drug effects , Extensively Drug-Resistant Tuberculosis/*drug therapy , Mycobacterium tuberculosis/*drug effects , Tuberculosis, Multidrug-Resistant/*drug therapy, Antitubercular Agents/chemistry ; Extensively Drug-Resistant Tuberculosis/pathology ; Humans ; Microbial Sensitivity Tests ; Molecular Structure ; Tuberculosis, Multidrug-Resistant/pathology
مستخلص: Human tuberculosis (TB) is primarily caused by Mycobacterium tuberculosis (Mtb) that inhabits inside and amidst immune cells of the host with adapted physiology to regulate interdependent cellular functions with intact pathogenic potential. The complexity of this disease is attributed to various factors such as the reactivation of latent TB form after prolonged persistence, disease progression specifically in immunocompromised patients, advent of multi- and extensivelydrug resistant (MDR and XDR) Mtb strains, adverse effects of tailor-made regimens, and drug-drug interactions among anti-TB drugs and anti-HIV therapies. Thus, there is a compelling demand for newer anti-TB drugs or regimens to overcome these obstacles. Considerable multifaceted transformations in the current TB methodologies and molecular interventions underpinning hostpathogen interactions and drug resistance mechanisms may assist to overcome the emerging drug resistance. Evidently, recent scientific and clinical advances have revolutionised the diagnosis, prevention, and treatment of all forms of the disease. This review sheds light on the current understanding of the pathogenesis of TB disease, molecular mechanisms of drug-resistance, progress on the development of novel or repurposed anti-TB drugs and regimens, host-directed therapies, with particular emphasis on underlying knowledge gaps and prospective for futuristic TB control programs.
(Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
فهرسة مساهمة: Keywords: Bedaquiline; Delamanid; Drug resistance; Host-directed therapy; MDR-TB; Mycobacterium tuberculosis; Tuberculosis
المشرفين على المادة: 0 (Antitubercular Agents)
تواريخ الأحداث: Date Created: 20201215 Date Completed: 20210719 Latest Revision: 20210719
رمز التحديث: 20240628
DOI: 10.2174/1568026621999201211200447
PMID: 33319660
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-4294
DOI:10.2174/1568026621999201211200447